Cryoport - CYRX Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cryoport in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYRX shares.
View CYRX analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12-month target prices for Cryoport's stock. Their CYRX share price forecasts range from $42.00 to $92.00. On average, they predict the company's share price to reach $61.33 in the next year. This suggests a possible upside of 143.7% from the stock's current price.
View analysts price targets for CYRX or view top-rated stocks among Wall Street analysts.

Cryoport's stock was trading at $59.17 at the beginning of 2022. Since then, CYRX stock has decreased by 57.5% and is now trading at $25.17.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CYRX earnings forecast.

Cryoport, Inc. (NASDAQ:CYRX) issued its quarterly earnings data on Thursday, August, 4th. The consumer goods maker reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.08. The consumer goods maker had revenue of $64.20 million for the quarter, compared to analyst estimates of $64.58 million. Cryoport had a negative trailing twelve-month return on equity of 14.43% and a negative net margin of 125.96%. The firm's revenue was up 14.2% on a year-over-year basis. During the same period last year, the business earned ($0.16) earnings per share.

Cryoport issued an update on its FY 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $260.00 million-$265.00 million, compared to the consensus revenue estimate of $260.62 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryoport investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Amarin (AMRN), QUALCOMM (QCOM), Enterprise Products Partners (EPD), Pfizer (PFE) and Block (SQ).

Cryoport trades on the NASDAQ under the ticker symbol "CYRX."

Cryoport's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Macquarie Group Ltd. (3.75%), Victory Capital Management Inc. (2.83%), Clearbridge Investments LLC (2.50%), State Street Corp (2.22%), Massachusetts Financial Services Co. MA (2.13%) and Granite Investment Partners LLC (1.86%). Insiders that own company stock include Daniel M Hancock, Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Michael R Egeck, Richard J Berman, Robert J Hariri and Robert Stefanovich.
View institutional ownership trends.

Shares of CYRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYRX stock can currently be purchased for approximately $25.17.

Cryoport (NASDAQ:CYRX) has a market capitalization of $1.22 billion and generates $222.61 million in revenue each year. The consumer goods maker earns $-275,530,000.00 in net income (profit) each year or ($6.18) on an earnings per share basis.

The company employs 791 workers across the globe.

Cryoport's mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The official website for the company is www.cryoport.com. The consumer goods maker can be reached via phone at (949) 470-2300, via email at tfromer@kcsa.com, or via fax at 949-470-2306.